COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Sunitinib Malate in Treating Patients With Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00943839
Recruitment Status : Completed
First Posted : July 22, 2009
Last Update Posted : November 10, 2016
Information provided by (Responsible Party):
Centre Antoine Lacassagne

Brief Summary:

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This clinical trial is studying how well sunitinib malate works in treating patients with kidney cancer.

Condition or disease Intervention/treatment Phase
Kidney Cancer Drug: sunitinib malate Other: laboratory biomarker analysis Other: pharmacological study Not Applicable

Detailed Description:



  • To determine whether a link exists between the effectiveness of therapy with sunitinib malate and development of blood biomarkers, specifically the angiogenic factors VEGF and interleukin-8 (IL-8), in patients with kidney cancer.


  • To evaluate the link between the time to progression and the development of VEGF and IL-6 CXCL7 and CXCK5 blood levels in these patients.
  • To evaluate the link between VEGF and IL-6 CXCL7 and CXCK5 blood levels and disease-free survival of these patients after 3, 6, 9, and 12 months of treatment.
  • To evaluate the link between VEGF and IL-6 CXCL7 and CXCK5 blood levels and overall survival of these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and then every 6 weeks for pharmacokinetic analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Sunitinib in the Expression of VEGF and of Interleukin 6 and CXCL7 - CXCL5 Cytokins : Explanation of Anti-angiogenic Effects.
Study Start Date : February 2009
Actual Primary Completion Date : November 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Cancer

Arm Intervention/treatment
Experimental: SUVEGIL Drug: sunitinib malate
Other: laboratory biomarker analysis
Other: pharmacological study

Primary Outcome Measures :
  1. Disease response [ Time Frame: 5 years ]
  2. VEGF and IL-8 blood levels determined before and every 6 weeks during treatment [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Length of the response [ Time Frame: up to 5 years ]
  2. Disease-free survival [ Time Frame: up to 5 years ]
  3. Overall survival [ Time Frame: up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed renal cell carcinoma
  • Metastatic disease requiring first-line treatment with sunitinib malate

    • No prior therapy for metastatic disease
  • No symptomatic or uncontrolled cerebral metastasis


  • Affiliation to the French Social insurance
  • Life expectancy ≥ 3 months
  • No heart failure
  • No chronic unstable disease
  • No long QT interval
  • No history of another primary cancer
  • No severe, uncontrolled acute infection
  • No severe, uncontrolled hypertension
  • No psychological disorder


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00943839

Layout table for location information
Centre Antoine Lacassagne
Nice, France, 06189
Sponsors and Collaborators
Centre Antoine Lacassagne
Layout table for investigator information
Principal Investigator: Jean Marc Ferrero, MD Centre Antoine Lacassagne
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre Antoine Lacassagne Identifier: NCT00943839    
Other Study ID Numbers: CDR0000638415
First Posted: July 22, 2009    Key Record Dates
Last Update Posted: November 10, 2016
Last Verified: November 2015
Keywords provided by Centre Antoine Lacassagne:
stage IV renal cell cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Neoplasms
Carcinoma, Renal Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action